Sigyn Therapeutics appoints Jim Dorst, Richa Nand, and Christopher Wetzel to Board

Sigyn Therapeutics, Inc.

Appointments effective October 10, 2022; each director brings distinct expertise.
Jim Dorst: 30+ years finance/operations; former Director of Corporate Development at SYNNEX/Concentrix and CFO of Aethlon Medical.
Richa Nand: IP attorney and founder of Insight Patents; biomedical researcher background at Cedars Sinai.
Christopher Wetzel: CEO of Surgery Center at Hamilton since 2004; long-term investor in extracorporeal therapy.
Board cited each director's experience in financial expertise, IP, or healthcare delivery as qualification.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jim Dorst

Director

SIGY · Sigyn Therapeutics, Inc.

Effective: 2022-10-10
Filed: October 5, 2022, 7:59 PM ET

The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.

Appointed

Christopher Wetzel

Director

SIGY · Sigyn Therapeutics, Inc.

Effective: 2022-10-10
Filed: October 5, 2022, 7:59 PM ET

The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.

Appointed

Richa Nand

Director

SIGY · Sigyn Therapeutics, Inc.

Effective: 2022-10-10
Filed: October 5, 2022, 7:59 PM ET

The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jim Dorst was appointed as Director at Sigyn Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Christopher Wetzel was appointed as Director at Sigyn Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Richa Nand was appointed as Director at Sigyn Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

The Board of Directors of Sigyn Therapeutics, Inc. (“the Company”) appointed Jim Dorst, Richa Nand, and Christopher Wetzel to the Company’s Board of Directors effective as of October 10, 2022.

View on SEC.gov

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-027728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.